Chinese biotech firm Biocytogen bags $142m Series D+ led by CMB International

Chinese biotech firm Biocytogen bags $142m Series D+ led by CMB International

Gut microbiome. Credit: Natural Health 365

Beijing-based biotechnology platform Biocytogen has announced the completion of a 970 million yuan ($142 million) Series D+ round led by returning backer CMB International, a Hong Kong-based subsidiary of China Merchants Bank. 

The round saw participation from a clutch of returning investors — SDIC Venture Capital, Chinese insurance group China Life’s equity investment arm China Life Investment Holding Company, healthcare-focused 3E Bioventures Capital, and Shenzhen-based Cowin Capital. New investor Baifu Capital also participated, Biocytogen announced on WeChat on Tuesday.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter